"The authors conclude that, with the exception of small increases in birth weight and length of gestation, n-3 PUFA [EPA/DHA] supplementation or fortification has no effects on peripartum maternal or infant health outcomes. No effects of n-3 PUFA [EPA/DHA] were seen on gestational hypertension, peripartum depression, or postnatal growth. Apparent effects of n-3 PUFA [EPA/DHA] supplementation were inconsistent across assessment methods and follow-up times for outcomes related to infant visual acuity, cognitive development, and prevention of allergy and asthma. [...]
[...]
Collectively, based on the three qSRs [qualified systematic reviews] described earlier, there is inconclusive evidence to support or refute the practice of giving n-3 PUFA [EPA/DHA] supplementation to pregnant and/or breastfeeding mothers in order to improve neurodevelopment or visual acuity. [...]
[...]
Concluding remarks
Based on randomized trials, there is inconclusive evidence to support or refute the practice of giving n-3 PUFA [EPA/DHA] supplementation to pregnant and/or breastfeeding mothers in order to improve neurodevelopment or visual acuity or reduce the risk of allergies in their children. However, supplementation during pregnancy may reduce the risk of asthma and/or wheeze in the offspring, but the strength of evidence is low." Retterstøl & Rosqvist 2023
Reference
Kjetil Retterstøl, Fredrik Rosqvist: Fat and fatty acids - a scoping review for Nordic Nutrition Recommendations 2023. Food Nutr Res. 2024 Jan 12:68. doi: 10.29219/fnr.v68.9980. eCollection 2024. https://pubmed.ncbi.nlm.nih.gov/38327998/